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Recent alerts and recalls regarding the use 
of infusion pumps highlight the importance 
of an interdisciplinary approach to equip-
ment design. HCI specialists are well placed 
to contribute and there are resources that 
allow developers to take account of the 
interaction between users, the tools that 
they use and the environments in which 
they live and work. HCI professionals need 
to make it easy for developers to adopt 
a user-centred approach and research is 
underway to establish current practice and 
future needs. 
Each year, members of the UK health 
service perform approximately 15 million infu-
sions. A small number (about 700) result in 
an adverse event [1]. Several mechanisms 
are in place to learn from incidents, protect 
patients from harm and maintain quality of 
care [2]. An area of potential concern relates 
to the users’ inadvertent misprogramming of 
the device. These types of interaction error can 
be easily missed [3]. Much has been achieved 
in safeguarding the public and professionals 
from poor device design; however, there is still 
a need to understand where the medical device 
industry requires support and how HCI profes-
sionals can contribute. 
For the majority of medical devices used 
in the European Union, patients, public and 
clinicians are protected by a statutory frame-
work – the Medical Devices Directive [4]. 
This sets out essential requirements for audit, 
inspection, design, production, marketing, risk 
assessment and post marketing surveillance of 
a broad range of devices. The regulation com-
prises core essential requirements in addition 
to a series of optional harmonised standards. 
In terms of user interaction, the essential 
requirements are often non-specific, as in the 
two examples that follow:
The devices must be designed and 
manufactured in such a way that, when 
used under the conditions and for the 
purposes intended, they will not compro-
mise the clinical condition or the safety 
of patients, or the safety and health of 
users…
Devices must be designed and manu-
factured in such a way as to remove 
or minimize as far as is possible: the 
risk of injury, in connection with their 
physical features, including the volume/
pressure ratio, dimensional and where 
appropriate ergonomic features…
In the US, the Food and Drug Agency 
(FDA) is more prescriptive in requiring devel-
opers to demonstrate how human factors 
considerations were applied during product 
development. Consequently, there are several 
examples of manufacturers adopting a human 
factors approach [5, 6]. Following an exten-
sive recall of infusion pumps, the FDA has 
announced an initiative to improve the safety 
and effectiveness of infusion pumps. In a 
recent white paper, cause for concern is raised 
regarding user interface issues, such as “con-
fusing or unclear onscreen user instructions 
…” [7].
In the UK, there have been several alerts 
issued by the National Patient Safety Agency 
(NPSA). In 2004 a safer practice notice was 
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released, recommending interventions regarding 
procurement and equipment management. The 
resulting purchasing toolkit required buyers to 
assess usability and requested that user views 
are fed back to manufacturers [1]. Recently, 
a series of resources have become available, 
including guidelines regarding the design of 
electronic infusion devices [8]. 
International design standards, such as 
AAMI HE74, AAMI HE75, ISO/IEC 60601-
1-6 and ISO/IEC 62366, recommend an itera-
tive development approach involving phased 
design reviews and continual user input and 
evaluation. The cycle includes user research, 
conceptual development, generation of design 
requirements, design output (specifications), 
verification, validation, evaluation, deployment 
and post-market surveillance (as required by 
the Medical Devices Directive). Tools such 
as usability testing and risk analysis may be 
applied during multiple stages of the cycle. 
Conceptual development and user research 
provides an understanding of the relevant 
domain. This includes reviewing process and 
procedures, market research, associated 
product complaints, adverse incidents, context 
of use and system constraints. Tools such as 
scenarios, storyboards, use cases, personas or 
task analysis may apply and practitioners can 
conduct focus groups, interviews or literature 
reviews. This informs usability requirements, 
for example “95% of first time users will be 
able to load a set and program an infusion 
within two minutes or less”. There are several 
resources that can aid this process including 
usability heuristics [9] and formal risk man-
agement processes such as ISO 14971. While 
setting usability requirements is useful, it is 
not sufficient. The FDA, amongst others, is now 
asking: What about the 5% who fail to achieve 
this objective – are they putting patients at risk 
by not correctly programming the infusion?
Despite the volume of support available, 
there is still a genuine need to understand 
how developers apply tools, where there is 
an absence of resources, and how models of 
human capability can inform interface design.
How do manufacturers provide for the 
usability requirements that arise as a result 
of home use? Do issues like alarm fatigue 
present opportunities to improve design? Does 
experience with a legacy device type impact on 
the use of a new device type? Is there a suf-
ficient understanding of how users react when 
distracted or when switching between multiple 
tasks? Do developers design interfaces that 
mitigate against likely sources of error and are 
there sufficient behavioural models to support 
this?
Interdisciplinary teams containing HCI 
specialists can contribute to many of these 
questions by recommending specific tools, 
techniques or measures and by providing clear 
and accessible advice that directly informs 
design decisions. HCI professionals can help 
the development team adopt formal methods 
to structure testing; they can also help produce 
tests that consider relevant human capabili-
ties during the iterative process of prototyping, 
simulation and usability testing.
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Understanding how and why interface 
developers make design decisions is part of 
the CHI+MED research programme (http://
www.chi-med.ac.uk/). It involves contributing 
methods that minimise the risk of human error 
and maximise patient benefit. Input from HCI 
practitioners and health care professionals is 
essential in understanding current practice 
and future needs, particularly with regard 
to interaction design. For more information, 
or to get involved, contact Chris Vincent at 
University College London Interaction Centre 
(UCLIC), c.vincent@ucl.ac.uk or +44 (0)20 
7679 0694.
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